Parkinson’s disease and motor fluctuations
PureIMS B.V. is involved in clinical research related to Parkinson’s disease, with a therapeutic interest in managing episodic OFF episodes in adults receiving levodopa and a dopa-decarboxylase inhibitor.
- Intermittent treatment of motor fluctuations
- OFF episode control
- Levodopa-based therapy
The sponsor’s current clinical activity is centered on inhaled delivery options for symptoms associated with fluctuating Parkinsonian response.
Inhaled levodopa delivery
The trial portfolio includes research on oral inhalation of levodopa, reflecting interest in non-oral administration routes for rapid therapeutic effect.
- Inhalation-based delivery
- Levodopa absorption
- Respiratory administration
This area of work focuses on how inhaled levodopa can be used in adult patients who need fast symptom relief during motor “off” periods.
Bioavailability and comparative pharmacokinetics
PureIMS B.V. is also engaged in research assessing the bioavailability of levodopa across different inhaled formulations, with attention to how exposure compares with an established reference product.
- Comparative bioavailability
- Pharmacokinetic performance
- Reference-product comparison
These activities support the development of inhaled levodopa options for use in Parkinson’s disease care.
